Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16652
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJackson, Belinda-
dc.contributor.authorCon, Danny-
dc.contributor.authorMa, Ronald-
dc.contributor.authorGorelik, Alexandra-
dc.contributor.authorLiew, Danny-
dc.contributor.authorDe Cruz, Peter-
dc.date2017-05-16-
dc.date.accessioned2017-05-24T02:00:35Z-
dc.date.available2017-05-24T02:00:35Z-
dc.date.issued2017-08-
dc.identifier.citationScandinavian Journal of Gastroenterology 2017; 52(8): 851-856en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16652-
dc.description.abstractIntroduction: We aimed to describe the total costs of illness for IBD patients and compare the costs of patients with active disease to those with inactive disease. Materials and methods: Resource use for IBD management was itemized for attributable costs (AUD) among all IBD patients over a 12-month period at an Australian hospital. Results: One hundred and eighty-three patients were included (87 ulcerative colitis (UC); 93 Crohn’s disease (CD); three IBD-unclassified). The median (IQR) annual overall cost was higher in the CD versus UC group ($15,648 versus $5017; p < .001). The difference in cost between CD and UC was influenced by the difference in outpatient costs for CD patients $9602 ($4311–$29,805) versus $4867 ($3220–$7249), p < .001). The cost of treating patients with active disease was $3461 ($1607–$11,771) and was higher in the CD versus the UC group ($6098 ($2168–$16,471) versus $1638 ($1401–$3767); p = .026) and was influenced by inpatient admissions. The cost of treating patients in remission was $2090 ($1552–$12,954) and was higher in the CD versus the UC group [$7977 ($1579–$14,304) versus $1848 ($1508–$6601); p = .236]. Conclusions: There is a discrepancy in costs of inpatient versus outpatient IBD management and treating active disease compared with disease in remission. Proactive care may help prevent disease reaching a severity whereby reactive management of active disease is required.en_US
dc.subjectHealth care costsen_US
dc.subjectHealth economicsen_US
dc.subjectInflammatory bowel diseaseen_US
dc.titleHealth care costs associated with Australian tertiary inflammatory bowel disease careen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleScandinavian Journal of Gastroenterologyen_US
dc.identifier.affiliationDepartment of Gastroenterology, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationMelbourne Epicentre, The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28509590en_US
dc.identifier.doi10.1080/00365521.2017.1323117en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
crisitem.author.deptClinical Analytics and Reporting-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Feb 1, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.